Latest News Releases

Press background on Morepen Laboratories
Company profile
Some things will always remain unfettered. Like sunshine and air, like suffering and joy, like sharing and caring. Some things will never recognize the confines of space and time. Like human endeavour and enterprise, like the desire to touch life. At Morepen, we are taking our expertise and experience in Wellness to new countries and new people with an increasing focus on global exports. And in doing so, our spirit of caring is crossing boundaries.
 Recent press releases
Morepen Labs Reports 24% Rise in its Net Sales and 34% Rise in Net Profit in First Half of FY 2019-20 Led by a Significant Jump in its Bulk Drugs and Home Diagnostics Businesses

Highlights of First Half (H1) FY 2019-20 (Standalone)
Net Sales Revenue recorded a growth of 24.2 per cent at Rs. 383.30 crore in H1 FY 2019-20 as compared to Rs. 308.56 crore in the corresponding first half of the previous fiscal.
EBIDTA was up by 31.... (more)
Morepen Labs Adds three New Drugs - Rivaroxaban, Vildagliptin and UDCA to its API Portfolio

Three new Drugs viz., Rivaroxaban (Cardiac Segment), Vildagliptin (Diabetes segment) and UDCA (for Liver ailments) added to API portfolio.
Commercial launch of all the three drugs announced by the company, supplies to commence soon.
Global market size of Rivaroxaban... (more)
Morepen Labs Catches Pharma Sector Uptrend in Q1 FY 2019-20. Company’s Net Profit Rises by a Whopping 256 Percent Led by a Significant Jump in its APIs Exports

Highlights Q1 FY 2019-20 (Standalone):
Net Sales Revenue recorded a pure organic growth of 25.4 per cent at Rs. 186.70 crore in Q1’FY 2019-20 as compared to Rs. 148.83 crore in the corresponding quarter of the previous fiscal
Net ... (more)
Morepen Labs Profit Rises by 125 Percent in Q4 FY 2018-19 Led by Good Growth in All Business Segments

Highlights Q4 FY 2018-19
Total Revenue (Standalone) up by 31 percent at Rs. 207.10 crore and Consolidated Total Revenue up by 28 percent at Rs. 219.74 crore registering a good growth in all business segments.
Standalone Net Profit (PAT) is up by 125 pe... (more)
Morepen Labs begins FY 2018-19 with a Sound Performance in the First Quarter

Highlights Q1 FY 2018-19 (Consolidated)
Net Sales Revenue up by 26 percent at Rs. 161.81 crore backed by improved sales revenue from Home Diagnostics, Formulations and OTC Businesses.
Domestic sales up by 71 percent at Rs. 108.20 crore. EBIDTA rises by 1... (more)
Twin USFDA Approvals for Morepen Labs’ Bulk Drugs (API) Facilities

Key Highlights
Baddi facility in Himachal Pradesh gets USFDA approval for cholesterol reducing bulk drug “Atorvastatin”.
Masulkhana facility, also in Himachal Pradesh, gets USFDA approval for an anti-asthma bulk drug “Montelukast Sodium”.
... (more)
Morepen Labs Reports Growth-filled Fourth Quarter to Close FY 2017-18 with a 25 Per cent Rise in its Net Profit

Highlights 12M FY 2017-18 (Consolidated)
Net profit rises by 25 per cent at Rs. 29.59 Crore.
Net Sales Revenue up by 1.9 per cent at Rs. 598 crore.
Domestic sales up by 21.3 per cent at Rs. 414 crore.
The overall Home Diagnostic categor... (more)
Morepen Labs Boards the Growth Ladder with the Peer Group in the Healthcare and Pharmaceutical Sector

Highlights Q3 FY 2017-18
107% increase in Net profit at Rs. 9.67 crore.
Cash profits increase by 32%
EBIDTA growth by 18%
Net Sales Revenue marginally up by 1.9% at Rs. 140 crore.
Domestic Sales are up by 25 per cent at Rs. 10... (more)
Morepen Gets US FDA Clearance for its Bulk Drug Montelukast Sodium

The United States Food and Drug Administration (USFDA) has cleared Montelukast Sodium, a bulk drug / API manufactured by Morepen Laboratories Ltd., for sale in the US market. This gives Morepen an entry into the Rs. 2000 crore (Approx. $ 300 million) US market for Montelukast. The first com... (more)
Morepen Labs Reports 24 Per cent Jump in its Q2 Net Profit Backed by Lower Interest Cost and Improved Home Diagnostics’ Sales

Highlights Q2 FY 2017-18
Net profit rises by 24 per cent at Rs. 10.37 Crore.
Net Sales Revenue declines marginally by 3 per cent at Rs. 136.43 crore.
Domestic Sales are up by 34.4 per cent at Rs. 101.91 crore.
Exports turnover stood at ... (more)
Joomla25 Appliance - Powered by TurnKey Linux